Cosmo Bio Co Ltd

Cosmo Bio maintains a strong liquidity position, with cash and equivalents amounting to ¥3.025 billion, representing 25.76% of total assets. The company's current ratio of 7.36 indicates a robust ability to meet short-term obligations, and its long-term debt is minimal at ¥20 million, contributing to a debt-to-equity ratio of 0.0. The price-to-book ratio of 0.76 suggests the market values the company at a discount to its book value, while the price-to-tangible-book ratio is identical, indicating no significant intangible assets.

Profitability metrics for Cosmo Bio are modest. The company reported a net income of ¥28 million and an operating income of ¥14 million, translating to a return on equity (ROE) of 0.3% and a return on assets (ROA) of 0.24%. These figures are below the typical thresholds for pharmaceutical firms, which often aim for ROE above 10% and ROA above 5%. The gross profit of ¥726 million represents a 33.2% margin, which is in line with industry norms but does not reflect strong operational efficiency.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segmentation detail limits the ability to assess regional exposure or potential risks from overreliance on a specific market. The company's operating cash flow of ¥309 million supports its capital expenditures of -¥92 million, indicating a net cash inflow that could be used for growth or debt reduction.

Cosmo Bio's revenue of ¥2.186 billion in the latest period suggests a stable but modest growth trajectory. Analyst estimates for revenue and EPS are not significantly different from reported figures, indicating a lack of strong growth expectations in the near term. The company's price-to-earnings ratio of 249.33 is extremely high, suggesting that the market is either pricing in very low earnings or is speculative in nature.

The risk assessment for Cosmo Bio indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt levels and strong cash position reduce financial risk, and the absence of dilution potential suggests that the capital structure is stable. However, the high P/E ratio could be a red flag for investors concerned about earnings sustainability.

Recent events, as reflected in the latest financial filings, show no significant changes in the company's operations or financial strategy. The company's capital expenditures are negative, indicating a reduction in investment, which may signal a focus on cost control rather than expansion. The absence of recent major events or strategic announcements suggests a period of operational stability but limited visibility into future growth initiatives.

Revenue grew 7.3% year-over-year to JPY 10.8 billion, demonstrating top-line expansion momentum in the latest fiscal period.

Net income surged 28.1% year-over-year to JPY 337 million, indicating a significant recovery in bottom-line profitability.

The company maintains a debt-to-equity ratio of 0.0, ranking above the 75th percentile for financial stability within its cohort.

Cash conversion stands at 11.04, significantly outperforming the cohort median of 0.95 and highlighting superior operational efficiency.

Gross profit increased to JPY 3.7 billion in FY2026, suggesting improved cost management or favorable product mix dynamics.

Net margin of 1.28% is substantially below the cohort median of 3.9%, highlighting persistent profitability issues relative to peers.

Revenue ¥3.33B, +7,7% YoY; Operating income −1,9% YoY.

• ▍Revenue ¥3.33B, +7,7% YoY
• ▍Operating income −1,9% YoY
• ▍Net income +4,7% YoY
• ▍Net margin 6.7%

Revenue ¥2.88B, +9,6% YoY; Operating income +120,8% YoY.

• ▍Revenue ¥2.88B, +9,6% YoY
• ▍Operating income +120,8% YoY
• ▍Net income +317,2% YoY
• ▍Net margin 2.2%

Revenue ¥2.48B, +8,9% YoY; Operating income −59,1% YoY.

• ▍Revenue ¥2.48B, +8,9% YoY
• ▍Operating income −59,1% YoY
• ▍Net income −30,3% YoY
• ▍Net margin 0.9%

Revenue ¥2.31B, +5,6% YoY; Operating income −121,4% YoY.

• ▍Revenue ¥2.31B, +5,6% YoY
• ▍Operating income −121,4% YoY
• ▍Net income +35,7% YoY
• ▍Net margin 1.6%

Revenue ¥3.09B; Operating income ¥268.0M.

• ▍Revenue ¥3.09B
• ▍Operating income ¥268.0M
• ▍Net margin 6.9%

Revenue ¥2.63B; Operating income -¥77.0M.

• ▍Revenue ¥2.63B
• ▍Operating income -¥77.0M
• ▍Net margin -1.1%

Revenue ¥2.28B; Operating income ¥22.0M.

• ▍Revenue ¥2.28B
• ▍Operating income ¥22.0M
• ▍Net margin 1.4%

Revenue ¥2.19B; Operating income ¥14.0M.

• ▍Revenue ¥2.19B
• ▍Operating income ¥14.0M
• ▍Net margin 1.3%

Revenue ¥10.77B, +7,3% YoY; Operating income +8,6% YoY.

• ▍Revenue ¥10.77B, +7,3% YoY
• ▍Operating income +8,6% YoY
• ▍Net income +28,1% YoY
• ▍Free cash flow −184,4% YoY
• ▍Net margin 3.1%

Revenue ¥10.04B, +7,5% YoY; Operating income −51,1% YoY.

• ▍Revenue ¥10.04B, +7,5% YoY
• ▍Operating income −51,1% YoY
• ▍Net income −40,6% YoY
• ▍Free cash flow −114,4% YoY
• ▍Net margin 2.6%

Revenue ¥9.34B, −2,2% YoY; Operating income −30,6% YoY.

• ▍Revenue ¥9.34B, −2,2% YoY
• ▍Operating income −30,6% YoY
• ▍Net income −14,3% YoY
• ▍Free cash flow −12,3% YoY
• ▍Net margin 4.7%

Revenue ¥9.55B, +3,5% YoY; Operating income −24,9% YoY.

• ▍Revenue ¥9.55B, +3,5% YoY
• ▍Operating income −24,9% YoY
• ▍Net income −29,9% YoY
• ▍Free cash flow −37,5% YoY
• ▍Net margin 5.4%